Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: Implications for the diagnostic role of imaging

Clinical Nuclear Medicine

Volumn 35, Issue 5, 2010, Pages 311-316

  Marini, Cecilia ^a   Di Poggio, Monica Bandettini ^b   Pomposelli, Elena ^b   Marchese, Roberta ^b   Nobili, Flavio ^c   Morbelli, Silvia D ^b   Villa, Giuseppe ^b   Abbruzzese, Giovanni ^b   Sambuceti, Gianmario ^b,d  

^a CNR   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Advanced Biotechnology Center   (Italy)

Author keywords

MIBG; Multiple system atrophy; Parkinson disease; Tracer kinetics

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADREVIEW; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG RETENTION; DRUG UPTAKE; FEMALE; FOLLOW UP; HEART SCINTISCANNING; HUMAN; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; SHY DRAGER SYNDROME; WHOLE BODY SCINTISCANNING;

3-IODOBENZYLGUANIDINE; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEART; HUMANS; INJECTIONS, INTRAVENOUS; KINETICS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; RADIOPHARMACEUTICALS; WHOLE BODY IMAGING;

EID: 77951272737     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181d62686     Document Type: Article

References (32)

1. Braune S, Reinhardt M, Bathmann J, et al. Impaired cardiac uptake of meta-[123I] iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol Scand. 1998;97:307-314. (Pubitemid 28191923)
2. Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I] MIBG separates Parkinson's disease from multiple system atrophy. Neurology. 1999;53:1020-1025. (Pubitemid 29442118)
3. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci. 2000;175:3-12. (Pubitemid 30227477)
4. Orimo S, Ozawa E, Nakade S, et al. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:189-194. (Pubitemid 29326950)
5. Satoh A, Serita T, Seto M, et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med. 1999;40:371-375. (Pubitemid 29120107)
6. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998; 155:60-67. (Pubitemid 28141060)
7. Orimo S, Takahashi A, Uchilhara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol. 2007;17:24-30. (Pubitemid 46310676)
8. Merlet P, Dubois-Rande JL, Adnot S, et al. Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992;19:10-16.
9. Kusmic C, Morbelli S, Marini C, et al. Whole-body evaluation of MIBG tissue extraction in a mouse model of long-lasting type II diabetes and its relationship with norepinephrine transport protein concentration. J Nucl Med. 2008;49:1701-1706.
10. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 myocardial meta-iodo-benzylguanidine washout and distribution may reflect myocardial adrenergic derangement in patients with congestive heart cardiomyopathy. Circulation. 1988;78:1192-1199.
11. Flotats A, Carrió I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11:587-602. (Pubitemid 39341804)
12. Marini C, Giorgetti A, Gimelli A, et al. Extension of myocardial necrosis differently affects MIBG retention in heart failure caused by ischaemic heart disease or by dilated cardiomyopathy. Eur J Nucl Med Mol Imaging. 2005; 32:682-688. (Pubitemid 40897491)
13. Courbon F, Brefel-Courbon C, Thalamas C, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord. 2003;18:890-897. (Pubitemid 37021163)
14. Kollensperger M, Seppi K, Liener C, et al. Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord. 2007;22:1771-1776. (Pubitemid 47597601)
15. Taki J, Yoshita M, Yamada M, et al. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders. Ann Nucl Med. 2004;18:453-461.
16. Nagayama H, Hamamoto M, Ueda M, et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2005;76:249-251. (Pubitemid 40143717)
17. Nagamachi S, Wakamatsu H, Kiyohara S, et al. Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy. Ann Nucl Med. 2008;22:557-564.
18. Arao T, Takabatake N, Sata M, et al. In vivo evidence of endothelial injury in chronic obstructive pulmonary disease by lung scintigraphic assessment of (123)I-meta-iodo-benzylguanidine. J Nucl Med. 2003;44:1747-1754. (Pubitemid 39663305)
19. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
20. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res. 1998;8:359-362. (Pubitemid 29021108)
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
22. Fahn S, Elton RL; UPDRS Program Members. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163, 293-304.
23. Mardon K, Montagne O, Elbaz N, et al. Uptake-1 carrier downregulates in parallel with the beta-adrenergic receptor desensitization in rat hearts chronically exposed to high levels of circulating norepinephrine: implications for cardiac neuroimaging in human cardiomyopathies. J Nucl Med. 2003;44: 1459-1466. (Pubitemid 39663360)
24. Orimo S, Ozawa E, Oka T, et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology. 2001;57: 1140-1141. (Pubitemid 32880227)
25. Orimo S, Oka T, Miura H, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurosurg Psychiatry. 2002;73:776-777. (Pubitemid 35448873)
26. Goldstein DS, Holmes C, Li ST, et al. Cardiac sympathetic denervation in Parkinson Disease. Ann Intern Med. 2000;133:338-347.
27. Goldstein DS, Holmes C, Dendi R, et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology. 2002;58:1247-1255. (Pubitemid 34411870)
28. Kanzaki N, Sato K, Haybara T. Improved cardiac iodine-123 metaiodobenzylguanidine accumulation after drug therapy in a patient with Parkinson's disease. Clin Nucl Med. 1997;22:697-699. (Pubitemid 28049452)
29. Camacho V, Carrió I. Targeting neuronal dysfunction and receptor imaging. Curr Opin Biotechnol. 2007;18:60-64. (Pubitemid 46227969)
30. Yoshita M. Cardiac uptake of 123 MIBG separates PD from multiple system atrophy. Neurology. 2000;54:1877-1878.
31. Takatsu H, Nagashima K, Murase M, et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA. 2000;284:44-45. (Pubitemid 30445658)
32. Gao DW, Talke PO, Dae MW. Effects of reduced sympathetic activity on myocardial metaiodobenzylguanidine (MIBG) washout. Auton Pharmacol. 2001;21:159-164.